WJ-Pure(WJ-Pure) - 在研适应症：慢性阻塞性肺疾病，阿尔茨海默症，杜氏肌营养不良症_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用机制-

治疗领域

呼吸系统疾病免疫系统疾病神经系统疾病+ [3]

在研适应症

慢性阻塞性肺疾病阿尔茨海默症杜氏肌营养不良症+ [1]

非在研适应症-

原研机构

Vitti Labs LLC.

在研机构

Vitti Labs LLC.

非在研机构-

最高研发阶段临床申请

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 WJ-Pure 相关的临床结果

登录后查看更多信息

100 项与 WJ-Pure 相关的转化医学

登录后查看更多信息

100 项与 WJ-Pure 相关的专利（医药）

登录后查看更多信息

19

项与 WJ-Pure 相关的文献（医药）

2024-09-18·Cancer Cell International

Enhanced anti-tumor efficacy of S3I-201 in breast cancer mouse model through Wharton jelly- exosome.

Article

作者: Salek Farrokhi, Amir ; Soudi, Sara ; Hosseini, Masoomeh ; Ezzeddini, Rana ; Hashemi, Seyed Mahmoud

OBJECTIVE:

Exosomes, membrane-enveloped vesicles found in various cell types, including Wharton's jelly mesenchymal stem cells, play a crucial role in intercellular communication and regulation. Their use as a cell-free nanotechnology and drug delivery system has attracted attention. Triple-negative breast cancer (TNBC) is a major global health problem and is characterized by a high mortality rate. This study investigates the potential of Wharton's Jelly mesenchymal stem cell-derived exosomes (WJ-Exo) as carriers of S3I-201 and their effects on STAT3 expression in breast cancer cell lines, and evaluates whether these exosomes can enhance the anti-tumor effect of S3I-201.

METHODS:

The filtered WJ-Exos were analyzed by Transmission Electron Microscopy (TEM), Scanning electron microscopy (SEM), Dynamic Light Scattering (DLS), flow cytometry, and Western blotting. These exosomes were then used for loading with S3I-201, resulting in the nano-formulation WJ-Exo(S3I-201). The effect of WJ-Exo(S3I-201) on 4T1 cancer cells was investigated in vitro using MTT assay, flow cytometry, wound healing assay, Western blotting and Quantitative Real-Time Polymerase chain reaction (qPCR) analysis. Finally, the therapeutic efficacy of the nano-formulation was investigated in vivo using a tumor-bearing mouse model.

RESULTS:

In vitro experiments showed that co-incubation of 4T1 cells with the nano-formulation resulted in a significant reduction in p-STAT3 levels, induction of apoptosis, modulation of Bcl-2, Bax and caspase-3 protein and gene expression, and inhibition of migration. In vivo, treatment of tumor-bearing mice with WJ-Exo(S3I-201) showed a strong antitumor effect that exceeded the efficacy observed in the S3I-201 group.

CONCLUSION:

Our results demonstrate that WJ-Exo is an effective carrier for targeting S3I-201 to tumor cells and enhances the therapeutic efficacy of S3I-201 in tumor-bearing mice.

2024-03-13·British medical bulletin

Wharton’s jelly and osteoarthritis of the knee

Review

作者: Potty, Anish G ; Maffulli, Nicola ; Aratikatla, Adarsh ; Gupta, Ashim ; Potti, Ishana A ; Gupta, Manu

Abstract:

Introduction:

The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee.

Source of data:

Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases.

Areas of agreement:

Perinatal tissues including Wharton’s jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA.

Areas of controversy:

The efficacy of WJ and associated MSCs in the management of knee OA is still controversial.

Growing points:

The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective.

Areas timely for developing research:

The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.

2022-12-01·BMC oral health

Efficiency of biofilm removal by combination of water jet and cold plasma: an in-vitro study

Article

作者: Kocher, Thomas ; Schlüter, Rabea ; Vilardell Scholten, Laura ; Eberhard, Christian ; Gerling, Torsten ; Seifert, Leo ; Holtfreter, Birte ; Pitchika, Vinay ; Matthes, Rutger ; Jablonowski, Lukasz

Abstract:

Background:

Peri-implantitis therapy is a major problem in implantology. Because of challenging rough implant surface and implant geometry, microorganisms can hide and survive in implant microstructures and impede debridement. We developed a new water jet (WJ) device and a new cold atmospheric pressure plasma (CAP) device to overcome these problems and investigated aspects of efficacy in vitro and safety with the aim to create the prerequisites for a clinical pilot study with these medical devices.

Methods:

We compared the efficiency of a single treatment with a WJ or curette and cotton swab (CC) without or with adjunctive use of CAP (WJ + CAP, CC + CAP) to remove biofilm in vitro from rough titanium discs. Treatment efficacy was evaluated by measuring turbidity up to 72 h for bacterial re-growth or spreading of osteoblast-like cells (MG-63) after 5 days with scanning electron microscopy. With respect to application safety, the WJ and CAP instruments were examined according to basic regulations for medical devices.

Results:

After 96 h of incubation all WJ and CC treated disks were turbid but 67% of WJ + CAP and 46% CC + CAP treated specimens were still clear. The increase in turbidity after WJ treatment was delayed by about 20 h compared to CC treatment. In combination with CAP the cell coverage significantly increased to 82% (WJ + CAP) or 72% (CC + CAP), compared to single treatment 11% (WJ) or 10% (CC).

Conclusion:

The newly developed water jet device effectively removes biofilm from rough titanium surfaces in vitro and, in combination with the new CAP device, biologically acceptable surfaces allow osteoblasts to grow. WJ in combination with CAP leads to cleaner surfaces than the usage of curette and cotton swabs with or without subsequent plasma treatment. Our next step will be a clinical pilot study with these new devices to assess the clinical healing process.

100 项与 WJ-Pure 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床申请	美国	Vitti Labs LLC.	2022-01-30
阿尔茨海默症	临床前	美国	Vitti Labs LLC.	2022-01-30
杜氏肌营养不良症	临床前	美国	Vitti Labs LLC.	2022-01-30
骨关节炎	临床前	美国	Vitti Labs LLC.	2022-01-30